Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

December 2024

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions
EFFECTIVE 1 DECEMBER 2024

- Amoxicillin with clavulanic acid (Augmentin) grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml, 100 ml – addition of PSS
- Beta-hCG low sensitivity urine test kit (CheckToP) midstream – new listing
- Betamethasone valerate (Betnovate) lotn 0.1%, 50 ml – price increase and addition of PSS
- Cisplatin (Cisplatin Accord) inj 1 mg per ml, 50 ml vial – new listing
- Compound electrolytes (Plasma-Lyte 148) inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 500 ml and 1,000 ml bag – price increase
- Compound electrolytes with glucose [dextrose] (Plasma-Lyte 148 & 5% Glucose) inj sodium 140 mmol/l, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, glucose 23 mmol/l (5%), 1,000 ml bag – price increase
- Compound sodium lactate [hartmann's solution] (Baxter) inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 500 ml and 1,000 ml bag – price increase
- Dexamfetamine sulfate (Noumed Dexamfetamine) tab 5 mg – amended restriction criteria
- Efavirenz (Stocrin) tab 200 mg and tab 600 mg – delisted 1 December 2024
- Empagliflozin (Jardiance) tab 10 mg and 25 mg – removal of note
- Empagliflozin with metformin hydrochloride (Jardiamet) tab 5 mg with 500 mg and 1,000 mg metformin hydrochloride and tab 12.5 mg with 500 mg and 1,000 mg metformin hydrochloride – removal of note
- Everolimus (Afinitor) tab 5 mg and 10 mg – amended restriction criteria
- Fentanyl (Boucher and Muir) inj 50 mcg per ml, 2 ml ampoule – price increase and addition of PSS
- Fentanyl (Boucher and Muir) inj 50 mcg per ml, 10 ml ampoule – addition of PSS
- Flecainide acetate (Almarytm) inj 10 mg per ml, 15 ml ampoule – new listing
- Gentamicin sulphate (Cidomycin P/Free) inj 40 mg per ml, 2 ml ampoule – new listing
- Glucose [dextrose] inj 5%, 50 ml bag (Baxter Glucose 5%), inj 10%, 1,000 ml bag (Baxter Glucose 10%), inj 10%, 500 ml bag (Baxter Glucose 10%) and inj 50%, 500 ml bag (Baxter Glucose 50%) – price increase
- Glucose with potassium chloride and sodium chloride (Baxter) inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, 1,000 ml bag, inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 1,000 ml bag and inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.9%, 1,000 ml bag – price increase

Summary of decisions – effective 1 December 2024 (continued)

- Glucose with sodium chloride (Baxter) inj glucose 2.5% with sodium chloride 0.45%, 500 ml bag – new listing
- Glucose with sodium chloride (Baxter) inj 4% glucose and sodium chloride 0.18%, 1,000 ml bag, inj 5% glucose and sodium chloride 0.45%, 1,000 ml bag and inj 5% glucose and sodium chloride 0.9%, 1,000 ml bag – price increase
- Heparin sodium (Wockhardt PSF) inj 1,000 iu per ml, 5 ml ampoule – new listing
- High protein oral feed 2.4 kcal/ml (e.g. Fortisip Compact Protein) liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml, 125 ml bottle – delisting delayed until 1 March 2025
- Hydroxychloroquine sulphate (Ipca-Hydroxychloroquine) tab 200 mg – new listing, addition of PSS, amended chemical name and restrictions removed
- Hydroxychloroquine sulphate (Plaquenil) tab 200 mg – to be delisted 1 May 2025
- Ipratropium bromide (Ipratropium IVAX) nebuliser soln 250 mcg per ml, 2 ml ampoule – to be delisted 1 February 2025
- Ipratropium bromide (Pharmascience) nebuliser soln 250 mcg per ml, 2 ml ampoule – to be delisted 1 May 2025
- Isoniazid (Noumed Isoniazid) tab 100 mg – new listing and addition of PSS
- Isoniazid (PSM) tab 100 mg – to be delisted 1 May 2025
- Lenvatinib (Lenvima) cap 4 mg and 10 mg – new listing
- Lisdexamfetamine dimesilate (Vyvanse) cap 30 mg, 50 mg and 70 mg – new listing
- Mannitol (Baxter) inj 10%, 1,000 ml bag and inj 20%, 500 ml bag – price increase
- Methylphenidate hydrochloride tab extended-release 18 mg, 27 mg, 36 mg and 54 mg (Concerta and Methylphenidate ER - Teva), tab immediate-release 5 mg, 10 mg and 20 mg (Rubifen), tab immediate-release 10 mg (Ritalin), tab sustained-release 20 mg (Rubifen SR) and cap modified-release 10 mg, 20 mg, 30 mg and 40 mg (Ritalin LA) – amended restriction criteria
- Methylthioninium chloride [methylene blue] (Proveblue) inj 5 mg per ml, 10 ml ampoule – price increase
- Modafinil (Modafinil Max Health) tab 100 mg – new listing, addition of PSS and amended restriction criteria
- Modafinil (Modavigil) tab 100 mg – to be delisted 1 May 2025
- Norethisterone (Noriday) tab 350 mcg – new listing
- Octreotide (Omega) inj 50 mcg per ml, 1 ml vial and inj 500 mcg per ml, 1 ml vial – new listing
- Pazopanib (Pazopanib Teva) tab 200 mg and 400 mg – new listing and addition of PSS
- Pazopanib (Votrient) tab 200 mg and 400 mg – to be delisted 1 May 2025

Summary of decisions – effective 1 December 2024 (continued)

- Potassium chloride with sodium chloride (Baxter) inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag, inj 20 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag, inj 40 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag and inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml bag – price increase
- Ringer's solution (Baxter) inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, 1,000 ml bag – new listing
- Salbutamol (Ventolin) oral liq 400 mcg per ml, 150 ml – price increase and addition of PSS
- Salbutamol with ipratropium bromide (Duolin Cipla) nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule – to be delisted 1 April 2025
- SGLT2 Inhibitors – amended restriction criteria
- Sodium chloride (Baxter) inj 0.45%, 500 ml bag, inj 3%, 1,000 ml bag and inj 0.9%, 50 ml, 100 ml, 250 ml, 500 ml and 1,000 ml bag – price increase
- Sodium chloride (Baxter Sodium Chloride 0.9%) irrigation soln 0.9%, 1,000 ml bottle – price increase
- Water (Baxter) inj, 1,000 ml bag – price increase
- Water (Baxter Water for Irrigation) irrigation soln, 1,000 ml bottle – price increase

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 December 2024

ALIMENTARY TRACT AND METABOLISM

11 SGLT2 Inhibitors (amended restriction criteria)

Restricted
Initiation – heart failure reduced ejection fraction
All of the following:
1 Patient has heart failure; and
2 Patient is in NYHA functional class II or III or IV; and
3 Either:
3.1 Patient has a documented left ventricular ejection fraction (LVEF) of less than or equal to 40%; or
3.2 An ECHO is not reasonably practicable, and in the opinion of the treating practitioner the patient would benefit from treatment; and
4 Patient is receiving concomitant optimal standard funded chronic heart failure treatment

Initiation – **Type 2 Diabetes**
Any of the following:
1 For continuation use; or
2 Patient has previously had an initial approval for a GLP-1 agonist; or
3 All of the following:
3.1 Patient has type 2 diabetes; and
3.2 Any of the following:
3.2.1 Patient is Māori or any Pacific ethnicity*; or
3.2.2 Patient has pre-existing cardiovascular disease or risk equivalent (see note a)*; or
3.2.3 Patient has an absolute 5-year cardiovascular disease risk of 15% or greater according to a validated Cardiovascular risk assessment calculator*; or
3.2.4 Patient has a high lifetime cardiovascular risk due to being diagnosed with type 2 diabetes during childhood or as a young adult*; or
3.2.5 Patient has diabetic kidney disease (see note b)*; and
3.3 Target HbA1c (of 53 mmol/mol or less) has not been achieved despite the regular use of at least one blood-glucose lowering agent (e.g. metformin, vildagliptin, or insulin) for at least 3 months.

Notes: * Criteria intended to describe patients at high risk of cardiovascular or renal complications of diabetes.
a) Pre-existing cardiovascular disease or risk equivalent defined as: prior cardiovascular disease event (i.e. angina, myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, transient ischaemic attack, ischaemic stroke, peripheral vascular disease), congestive heart failure or familial hypercholesterolaemia.
b) Diabetic kidney disease defined as: persistent albuminuria (albumin:creatinine ratio greater than or equal to 3 mg/mmol, in at least two out of three samples over a 3-6 month period) and/or eGFR less than 60 mL/min/1.73m^2 in the presence of diabetes, without alternative cause.
c) Funded [empagliflozin / empagliflozin with metformin hydrochloride] treatment is not to be given in combination with a funded GLP-1 unless receiving (empagliflozin / empagliflozin with metformin hydrochloride] for the treatment of heart failure.

12 EMPAGLIFLOZIN (removal of note)
~~Note: Not to be given in combination with a funded GLP-1 agonist.~~

➔ Tab 10 mg	58.56	30	Jardiance
➔ Tab 25 mg	58.56	30	Jardiance

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 December 2024 (continued)

12 EMPAGLIFLOZIN WITH METFORMIN HYDROCHLORIDE (removal of note)
~~Note: Not to be given in combination with a funded GLP-1 agonist.~~

➔ Tab 5 mg with 1,000 mg metformin hydrochloride	58.56	60	Jardiamet
➔ Tab 5 mg with 500 mg metformin hydrochloride	58.56	60	Jardiamet
➔ Tab 12.5 mg with 1,000 mg metformin hydrochloride	58.56	60	Jardiamet
➔ Tab 12.5 mg with 500 mg metformin hydrochloride	58.56	60	Jardiamet

BLOOD AND BLOOD FORMING ORGANS

36 HEPARIN SODIUM (new listing)

Inj 1,000 iu per ml, 5 ml ampoule	103.70	10	Wockhardt PSF

40 COMPOUND ELECTROLYTES (↑ price)

Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 500 ml bag	62.82	18	Plasma-Lyte 148
Inj sodium 140 mmol/l, potassium 5 mmol/l, magnesium 1.5 mmol/l, chloride 98 mmol/l, acetate 27 mmol/l, gluconate 23 mmol/l, 1,000 ml bag	30.72	12	Plasma-Lyte 148

40 COMPOUND ELECTROLYTES WITH GLUCOSE [DEXTROSE] (↑ price)

Inj sodium 140 mmol/l, 5 mmol/l potassium, 1.5 mmol/l magnesium, 98 mmol/l chloride, 27 mmol/l acetate and 23 mmol/l gluconate, glucose 23 mmol/l (5%), 1,000 ml bag	239.04	12	Plasma-Lyte 148 & 5% Glucose

40 COMPOUND SODIUM LACTATE [HARTMANN'S SOLUTION] (↑ price)

Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 500 ml bag	27.90	18	Baxter
Inj sodium 131 mmol/l with potassium 5 mmol/l, calcium 2 mmol/l, bicarbonate 29 mmol/l, chloride 111 mmol/l, 1,000 ml bag	19.32	12	Baxter

40 GLUCOSE [DEXTROSE] (↑ price)

Inj 5%, 50 ml bag	162.00	60	Baxter Glucose 5%
Inj 10%, 1,000 ml bag	162.00	12	Baxter Glucose 10%
Inj 10%, 500 ml bag	126.00	18	Baxter Glucose 10%
Inj 50%, 500 ml bag	423.00	18	Baxter Glucose 50%

40 GLUCOSE WITH POTASSIUM CHLORIDE AND SODIUM CHLORIDE (↑ price)

Inj 4% glucose with potassium chloride 20 mmol/l and sodium chloride 0.18%, 1,000 ml bag	240.36	12	Baxter
Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.45%, 1,000 ml bag	189.00	12	Baxter
Inj 5% glucose with potassium chloride 20 mmol/l and sodium chloride 0.9%, 1,000 ml bag	334.08	12	Baxter

40 GLUCOSE WITH SODIUM CHLORIDE (new listing)

Inj glucose 2.5% with sodium chloride 0.45%, 500 ml bag	318.78	18	Baxter

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 December 2024 (continued)

40	GLUCOSE WITH SODIUM CHLORIDE (↑ price)			
	Inj 4% glucose and sodium chloride 0.18%, 1,000 ml bag	192.96	12	Baxter
	Inj 5% glucose and sodium chloride 0.45%, 1,000 ml bag	192.84	12	Baxter
	Inj 5% glucose and sodium chloride 0.9%, 1,000 ml bag	204.84	12	Baxter
40	RINGER'S SOLUTION (new listing)			
	Inj sodium 147 mmol/l with potassium 4 mmol/l, calcium 2.2 mmol/l, chloride 156 mmol/l, 1,000 ml bag	227.52	12	Baxter
41	POTASSIUM CHLORIDE WITH SODIUM CHLORIDE (↑ price)			
	Inj 10 mmol potassium chloride with 0.29% sodium chloride, 100 ml bag	563.52	48	Baxter
	Inj 20 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag	192.72	12	Baxter
	Inj 40 mmol potassium chloride with 0.9% sodium chloride, 1,000 ml bag	299.40	12	Baxter
	Inj 40 mmol potassium chloride with 0.9% sodium chloride, 100 ml bag	912.96	48	Baxter
41	SODIUM CHLORIDE (↑ price)			
	Inj 0.45%, 500 ml bag	84.42	18	Baxter
	Inj 3%, 1,000 ml bag	165.84	12	Baxter
	Inj 0.9%, 50 ml bag	124.20	60	Baxter
	Inj 0.9%, 100 ml bag	88.80	48	Baxter
	Inj 0.9%, 250 ml bag	50.40	24	Baxter
	Inj 0.9%, 500 ml bag	27.54	18	Baxter
	Inj 0.9%, 1,000 ml bag	18.96	12	Baxter
42	WATER (↑ price)			
	Inj, 1,000 ml bag	24.12	12	Baxter

CARDIOVASCULAR SYSTEM

45	FLECAINIDE ACETATE (new listing)			
	Inj 10 mg per ml, 15 ml ampoule	102.79	5	Almarytm
49	MANNITOL (↑ price)			
	Inj 10%, 1,000 ml bag	882.84	12	Baxter
	Inj 20%, 500 ml bag	1,296.00	18	Baxter

DERMATOLOGICALS

69	BETAMETHASONE VALERATE (↑ price and addition of PSS)			
	Lotn 0.1% – **5% DV May-25 to 2027**	30.00	50 ml	**Betnovate**

GENITO-URINARY SYSTEM

74	NORETHISTERONE (new listing)			
	Tab 350 mcg	12.25	84	Noriday

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 December 2024 (continued)

INFECTIONS

87 GENTAMICIN SULPHATE (new listing)
Inj 40 mg per ml, 2 ml ampoule ..... 36.70 5 Cidomycin P/Free

91 AMOXICILLIN WITH CLAVULANIC ACID (addition of PSS)
Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml – **5% DV May-25 to 2027** ..... 8.50 100 ml **Augmentin**

99 ISONIAZID (new listing and addition of PSS)
➔ Tab 100 mg – **5% DV May-25 to 2027** ..... 327.41 100 **Noumed Isoniazid**
Note – PSM tab 100 mg to be delisted from 1 May 2025.

102 EFAVIRENZ (delisted)
➔ Tab 200 mg ..... 190.15 90 Stocrin
➔ Tab 600 mg ..... 63.38 30 Stocrin
Note – Stocrin tab 200 mg and 600 mg delisted 1 December 2024.

MUSCULOSKELETAL SYSTEM

111 HYDROXYCHLOROQUINE **SULPHATE** (new listing, addition of PSS, amended chemical name and restrictions removed)
➔ Tab 200 mg – **5% DV May-25 to 2027** ..... 7.80 100 **Ipca-Hydroxychloroquine**
~~Restricted~~
~~Initiation~~
~~Any of the following:~~
~~1 Rheumatoid arthritis; or~~
~~2 Systemic or discoid lupus erythematosus; or~~
~~3 Malaria treatment or suppression; or~~
~~4 Relevant dermatological conditions (cutaneous forms of lupus and lichen planus, cutaneous vasculitides and mucosal ulceration); or~~
~~5 Sarcoidosis (pulmonary and non-pulmonary).~~
Note – Plaquenil tab 200 mg to be from delisted 1 May 2025.

NERVOUS SYSTEM

123 FENTANYL (↑ price and addition of PSS)
Inj 50 mcg per ml, 2 ml ampoule – **5% DV May-25 to 2027** ..... 4.25 10 **Boucher and Muir**

123 FENTANYL (addition of PSS)
Inj 50 mcg per ml, 10 ml ampoule – **5% DV May-25 to 2027** .... 9.41 10 **Boucher and Muir**

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 December 2024 (continued)

142 LISDEXAMFETAMINE DIMESILATE (new listing)

➔Cap 30 mg	60.00	30	Vyvanse
➔Cap 50 mg	60.00	30	Vyvanse
➔Cap 70 mg	60.00	30	Vyvanse

Restricted
Initiation
Paediatrician or psychiatrist
Either:

1 Patient is currently on treatment with lisdexamfetamine dimesilate and met all remaining criteria prior to commencing treatment; or
2 All of the following
  2.1 ADHD (Attention Deficit and Hyperactivity Disorder); and
  2.2 Diagnosed according to DSM-V or ICD 11 criteria; and
  2.3 Any of the following:
    2.3.1 Patient is taking a currently subsidised formulation of atomoxetine or methylphenidate hydrochloride (extended-release) and has not received sufficient benefit or has experienced intolerable side effects; or
    2.3.2 Patient is taking a currently subsidised formulation of dexamfetamine sulfate (immediate-release) which has not been effective due to significant administration and/or treatment adherence difficulties; or
    2.3.3 There is significant concern regarding the risk of diversion or abuse of immediate release dexamfetamine sulfate; or
    2.3.4 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained release) which has not been effective due to significant administration and/or treatment adherence difficulties; or
    2.3.5 There is significant concern regarding the risk of diversion or abuse of immediate release methylphenidate hydrochloride; or
    2.3.6 Both:
      2.3.6.1 Patient would have been prescribed a subsidised formulation of methylphenidate hydrochloride (extended-release) but has been unable to access due to supply issues with methylphenidate hydrochloride (extended-release); and
      2.3.6.2 Other alternative stimulant presentations (methylphenidate or dexamfetamine) are not appropriate; and
  2.4 Lisdexamfetamine dimesilate is not to be used in combination with another funded methylphenidate presentation.

142 DEXAMFETAMINE SULFATE (amended restriction criteria – affected criteria shown only)

➔Tab 5 mg – **5% DV Jun-24 to 2025**	29.80	100	**Noumed Dexamfetamine**

Restricted
Initiation – Narcolepsy
Neurologist or respiratory specialist
~~*Re-assessment required after 24 months*~~
Patient suffers from narcolepsy.

~~Continuation – Narcolepsy~~
~~Neurologist or respiratory specialist~~
~~*Re-assessment required after 24 months*~~
~~The treatment remains appropriate and the patient is benefiting from treatment.~~

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 December 2024 (continued)

142 METHYLPHENIDATE HYDROCHLORIDE (amended restriction criteria – affected criteria shown only)

➔Tab extended-release 18 mg	58.96	30	Concerta
	7.75		Methylphenidate ER - Teva
➔Tab extended-release 27 mg	65.44	30	Concerta
	11.45		Methylphenidate ER - Teva
➔Tab extended-release 36 mg	71.93	30	Concerta
	15.50		Methylphenidate ER - Teva
➔Tab extended-release 54 mg	86.24	30	Concerta
	22.25		Methylphenidate ER - Teva
➔Tab immediate-release 5 mg	3.20	30	Rubifen
➔Tab immediate-release 10 mg	3.00	30	Ritalin
			Rubifen
➔Tab immediate-release 20 mg	7.85	30	Rubifen
➔Tab sustained-release 20 mg	10.95	30	Rubifen SR
➔Cap modified-release 10 mg	15.60	30	Ritalin LA
➔Cap modified-release 20 mg	20.40	30	Ritalin LA
➔Cap modified-release 30 mg	25.52	30	Ritalin LA
➔Cap modified-release 40 mg	30.60	30	Ritalin LA

Restricted
Initiation – Narcolepsy (immediate-release and sustained-release formulations)
Neurologist or respiratory specialist
~~Re-assessment required after 24 months~~
Patient suffers from narcolepsy.

~~Continuation – Narcolepsy (immediate-release and sustained-release formulations)~~
~~Neurologist or respiratory specialist~~
~~Re-assessment required after 24 months~~
~~The treatment remains appropriate and the patient is benefiting from treatment.~~

143 MODAFINIL (new listing, addition of PSS and amended restriction criteria)

➔Tab 100 mg – **5% DV May-25 to 2027**	14.27	30	**Modafinil Max Health**

Restricted
Initiation – Narcolepsy
Neurologist or respiratory specialist
~~Re-assessment required after 24 months~~
All of the following:
1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
2 Either:
  2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
  2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and
3 Either:
  3.1 An effective dose of a listed formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or
  3.2 Methylphenidate and dexamphetamine are contraindicated.

~~Continuation – Narcolepsy~~
~~Neurologist or respiratory specialist~~
~~Re-assessment required after 24 months~~
~~The treatment remains appropriate and the patient is benefiting from treatment.~~
Note – Modavigil tab 100 mg to be delisted 1 May 2025.

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 December 2024 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

157 CISPLATIN (new listing)

Inj 1 mg per ml, 50 ml vial	9.45	1	Cisplatin Accord

160 LENVATINIB (new listing)

➔ Cap 4 mg	3,407.40	30	Lenvima
➔ Cap 10 mg	3,407.40	30	Lenvima

Restricted
Initiation – thyroid cancer
Re-assessment required after 6 months
Either:
1 Patient is currently on treatment with lenvatinib and met all remaining criteria prior to commencing treatment; or
2 All of the following:
  2.1 The patient has locally advanced or metastatic differentiated thyroid cancer; and
  2.2 Either:
    2.2.1 Patient must have symptomatic progressive disease prior to treatment; or
    2.2.2 Patient must have progressive disease at critical anatomical sites with a high risk of morbidity or mortality where local control cannot be achieved by other measures; and
  2.3 Any of the following:
    2.3.1 A lesion without iodine uptake in a RAI scan; or
    2.3.2 Receiving cumulative RAI greater than or equal to 600 mCi; or
    2.3.3 Experiencing disease progression after a RAI treatment within 12 months; or
    2.3.4 Experiencing disease progression after two RAI treatments administered within 12 months of each other; and
  2.4 Patient has thyroid stimulating hormone (TSH) adequately supressed; and
  2.5 Patient is not a candidate for radiotherapy with curative intent; and
  2.6 Surgery is clinically inappropriate; and
  2.7 Patient has an ECOG performance status of 0-2.

Continuation – thyroid cancer
Re-assessment required after 6 months
There is no evidence of disease progression

Initiation – unresectable hepatocellular carcinoma
Re-assessment required after 6 months
All of the following:
1 Patient has unresectable hepatocellular carcinoma; and
2 Patient has preserved liver function (Childs-Pugh A); and
3 Transarterial chemoembolisation (TACE) is unsuitable; and
4 Patient has an ECOG performance status of 0-2; and
5 Patient has not received prior systemic therapy for their disease in the palliative setting.

Continuation – unresectable hepatocellular carcinoma
Re-assessment required after 6 months
There is no evidence of disease progression

Initiation – renal cell carcinoma
Re-assessment required after 4 months
Either:
1 All of the following:
  1.1 The patient has metastatic renal cell carcinoma; and
  1.2 The disease is of predominant clear-cell histology; and

continued...

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

Changes to Section H Part II – effective 1 December 2024 (continued)

continued...

1.3 The patient has documented disease progression following one previous line of treatment; and
1.4 The patient has an ECOG performance status of 0-2; and
1.5 Lenvatinib is to be used in combination with everolimus; or

2 All of the following:
2.1 Patient has received funded treatment with nivolumab for the second line treatment of metastatic renal cell carcinoma; and
2.2 Patient has experienced treatment limiting toxicity from treatment with nivolumab; and
2.3 Lenvatinib is to be used in combination with everolimus; and
2.4 There is no evidence of disease progression.

Continuation – renal cell carcinoma
Re-assessment required after 4 months
There is no evidence of disease progression.

161 PAZOPANIB (new listing and addition of PSS)

➔Tab 200 mg – **5% DV May-25 to 2027**	172.88	30	**Pazopanib Teva**
➔Tab 400 mg – **5% DV May-25 to 2027**	464.00	30	**Pazopanib Teva**

Note – Votrient tab 200 mg and 400 mg to be delisted from 1 May 2025.

167 OCTREOTIDE (new listing)

Inj 50 mcg per ml, 1 ml vial	27.58	5	Omega
Inj 500 mcg per ml, 1 ml vial	113.10	5	Omega

245 EVEROLIMUS (amended restriction criteria – new criteria shown only)

➔Tab 5 mg	4,555.76	30	Afinitor
➔Tab 10 mg	6,512.29	30	Afinitor

Restricted
Initiation – renal cell carcinoma
Re-assessment required after 4 months
Either:
1 All of the following:
1.1 The patient has metastatic renal cell carcinoma; and
1.2 The disease is of predominant clear-cell histology; and
1.3 The patient has documented disease progression following one previous line of treatment; and
1.4 The patient has an ECOG performance status of 0-2; and
1.5 Everolimus is to be used in combination with lenvatinib; or
2 All of the following:
2.1 Patient has received funded treatment with nivolumab for the second line treatment of metastatic renal cell carcinoma; and
2.2 Patient has experienced treatment limiting toxicity from treatment with nivolumab; and
2.3 Everolimus is to be used in combination with lenvatinib; and
2.4 There is no evidence of disease progression.

Continuation – renal cell carcinoma
Re-assessment required after 4 months
There is no evidence of disease progression.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 December 2024 (continued)

RESPIRATORY SYSTEM AND ALLERGIES

251 IPRATROPIUM BROMIDE (delisting)
Nebuliser soln 250 mcg per ml, 2 ml ampoule..... 11.73 20 Ipratropium IVAX
Note – Ipratropum IVAX nebuliser soln 250 mcg per ml, 2 ml ampoule to be delisted from 1 February 2025.

251 IPRATROPIUM BROMIDE (delisting)
Nebuliser soln 250 mcg per ml, 2 ml ampoule..... 5.86 10 Pharmascience
Note – Pharmascience nebuliser soln 250 mcg per ml, 2 ml ampoule to be delisted from 1 May 2025.

252 SALBUTAMOL WITH IPRATROPIUM BROMIDE (delisting)
Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule..... 11.04 20 Duolin Cipla
Note – Duolin Cipla nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule to be delisted from 1 April 2025.

254 SALBUTAMOL (↑ price and addition of PSS)
Oral liq 400 mcg per ml – **5% DV May-25 to 2027**..... 50.00 150 ml **Ventolin**

VARIOUS

271 METHYLTHIONINIUM CHLORIDE [METHYLENE BLUE] (↑ price)
Inj 5 mg per ml, 10 ml ampoule ..... 259.57 5 Proveblue

271 SODIUM CHLORIDE (↑ price)
Irrigation soln 0.9%, 1,000 ml bottle..... 19.50 10 Baxter Sodium Chloride 0.9%

272 WATER (↑ price)
Irrigation soln, 1,000 ml bottle ..... 19.50 10 Baxter Water for Irrigation

SPECIAL FOODS

293 HIGH PROTEIN ORAL FEED 2.4 KCAL/ML (delisting delayed)
Only to be used for patients currently on or would be using Fortisip or Fortisip Multi Fibre
➔ Liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml, 125 ml bottle *e.g. Fortisip Compact Protein*
Note – e.g. Fortisip Compact Protein liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml, 125 ml bottle to be delisted from 1 ~~December 2024~~ **March 2025**)

OPTIONAL PHARMACEUTICALS

307 BETA-HCG LOW SENSITIVITY URINE TEST KIT (new listing)
Note: for use in abortion services only.
Midstream..... 16.28 1 test CheckToP

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

Index

Pharmaceuticals and brands

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government